|Awarded On||August 20, 2014|
|Title||Intrinsic Reward Sensitivity & Smoking Cessation with Varenicline or Patch NRT|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Paul M Cinciripini|
|Cancer Sites||Bladder, Cervix Uteri, Head and Neck, Leukemia, Lung and Bronchus, Pancreas|
Cigarette smoking is still the major cause of preventable disease in the United States. The proposed research is relevant to public health because it proposes to develop a measure of brain activity that will help determine which smokers are more likely to benefit from varenicline or nicotine replacement therapy, prior to their receiving the drug. The medications have different levels of effectiveness and different side effects. Knowing which one works best for each person will help improve overall cessation since smokers would get the most effective treatment with the fewest side effects, based on the measure of brain activity we take before treatment begins.